Physician profile
Adam Wolff
NPI 1053349597
$364,117.23
in general payments reported to CMS, 2019-2025
96 companies · $171K in 2025
The $171K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,982 · 2021: $24K · 2022: $6,598 · 2023: $13K · 2024: $135K · 2025: $171K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $118K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Consulting Fee: $44K · Travel and Lodging: $38K · Food and Beverage: $30K · Education: $57.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $117,810.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,755.00 |
| Consulting Fee | $44,378.00 |
| Travel and Lodging | $37,675.96 |
| Food and Beverage | $29,552.49 |
| Education | $57.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $198,977.58 | 2019-2025 | |
| Lilly USA, LLC | $81,058.53 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $14,689.87 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| E.R. Squibb & Sons, L.L.C. | $12,915.39 | 2020-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $8,367.65 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $5,304.58 | 2019-2025 | Ubrelvy, Botox, Qulipta |
| Sk Life Science, INC. | $4,183.40 | 2020-2025 | Xcopri |
| Celgene Corporation | $3,756.00 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $3,544.10 | 2019-2025 | |
| Ucb, INC. | $2,314.94 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Csl Behring | $2,192.44 | 2019-2025 | Privigen, Hizentra |
| Allergan, INC. | $1,689.13 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $1,467.54 | 2019-2025 | Nuplazid, Daybue |
| Amgen INC. | $1,420.52 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $1,340.92 | 2019-2025 |
Show all 96 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,178.62 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Mdd US Operations, LLC | $1,173.18 | 2019-2025 | Gocovri, Gocovri |
| Teva Pharmaceuticals USA, INC. | $1,171.57 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Emd Serono, INC. | $1,166.18 | 2019-2025 | Mavenclad |
| Pfizer INC. | $1,131.74 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,090.94 | 2019-2025 | Ultomiris, Soliris |
| Merz Pharmaceuticals, LLC | $1,014.74 | 2021-2025 | Xeomin, Inbrija |
| Neuronetics, INC. | $912.06 | 2025 | Neurostar Tms Therapy System |
| Lundbeck LLC | $867.17 | 2019-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $701.27 | 2021-2025 | Valtoco |
| Argenx US, INC. | $592.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $590.18 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $558.68 | 2019-2025 | Dysport |
| Acorda Therapeutics, INC | $495.92 | 2019-2024 | Inbrija |
| Jazz Pharmaceuticals INC. | $494.56 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $481.19 | 2021 | |
| Sunovion Pharmaceuticals INC. | $439.38 | 2019-2022 | |
| Tanabe Pharma America, INC. | $425.15 | 2019-2025 | Radicava |
| Grt US Holding, INC. | $333.27 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $295.41 | 2025 | Rexulti |
| Mallinckrodt Hospital Products INC. | $283.38 | 2020-2025 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $275.00 | 2022 | |
| Grifols USA, LLC | $274.91 | 2019-2025 | Gamunex-C, Xembify |
| Supernus Pharmaceuticals, INC. | $264.89 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $264.16 | 2019 | |
| Livanova USA, INC. | $249.28 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $218.69 | 2019-2025 | Crexont |
| Abbott Laboratories | $207.40 | 2019-2025 | Infinity, Eterna |
| Ani Pharmaceuticals, INC. | $202.11 | 2022-2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $178.66 | 2024-2025 | Ponvory |
| Kyowa Kirin, INC. | $150.97 | 2019-2021 | |
| Merz North America, INC. | $144.95 | 2019-2020 | |
| Octapharma USA, INC. | $138.73 | 2022-2025 | Panzyga |
| Catalyst Pharmaceuticals, INC. | $137.69 | 2020-2025 | |
| Akcea Therapeutics, INC. | $133.72 | 2020-2021 | |
| Sobi, INC | $122.23 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $120.59 | 2023-2024 | Rexulti, Nuedexta |
| Alnylam Pharmaceuticals INC. | $120.29 | 2022-2024 | Onpattro |
| Janssen Pharmaceuticals, INC | $116.44 | 2021-2022 | |
| Axsome Therapeutics, INC. | $116.22 | 2025 | Symbravo |
| Microtransponder, INC. | $115.74 | 2025 | |
| Upsher-Smith Laboratories LLC | $105.70 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $102.53 | 2023 | Aptiom |
| Adamas Pharmaceuticals, INC. | $96.88 | 2019-2021 | |
| Banner Life Sciences, LLC | $91.95 | 2021-2024 | |
| Impel Pharmaceuticals INC. | $78.74 | 2022-2023 | Trudhesa |
| Scilex Pharmaceuticals INC. | $77.77 | 2023-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $77.60 | 2022 | |
| Averitas Pharma INC. | $76.74 | 2023-2025 | Qutenza |
| Avanir Pharmaceuticals, INC. | $75.78 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.55 | 2024 | Hyqvia |
| Janssen Biotech, INC. | $74.20 | 2025 | |
| Harmony Biosciences LLC | $73.06 | 2023-2025 | Wakix |
| Chiesi USA, INC. | $67.55 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $61.56 | 2023 | Relyvrio |
| Boston Scientific Corporation | $59.63 | 2024-2025 | General - Therapies, Vercise |
| Ge Healthcare | $56.50 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $54.45 | 2025 | Tascenso Odt, Bafiertam |
| Almatica Pharma LLC | $53.06 | 2020-2021 | |
| Strongbridge US INC. | $45.63 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $45.04 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $42.51 | 2023 | Quviviq |
| C2n Diagnostics, LLC | $38.42 | 2025 | Precivityad2 |
| Greenwich Biosciences, INC. | $37.97 | 2021 | |
| Horizon Therapeutics Plc | $37.28 | 2020-2023 | Uplizna |
| Promius Pharma LLC | $31.01 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.45 | 2019-2020 | |
| Saol Therapeutics INC. | $25.25 | 2019 | |
| Bausch Health US, LLC | $25.19 | 2019 | |
| Nevro Corp. | $24.71 | 2022 | |
| Gilead Sciences, INC. | $24.19 | 2019 | |
| Kedrion Biopharma INC. | $24.06 | 2021 | |
| Eli Lilly and Company | $23.29 | 2019-2025 | Kisunla |
| Astrazeneca Pharmaceuticals LP | $23.13 | 2022 | |
| Life Molecular Imaging LTD | $20.89 | 2025 | Neuraceq |
| Medtronic USA, INC. | $17.54 | 2019 | |
| Insightec,INC | $16.85 | 2023 | Exablate |
| Kedrion Biopharma, INC. | $16.47 | 2024 | Koate, Albuked, Kedrab |
| Avion Pharmaceuticals | $15.47 | 2023 | Dhivy |
| Vertical Pharmaceuticals, LLC | $13.20 | 2019 | |
| Bio Products Laboratory USA, INC. | $9.62 | 2023 | Coagadex, Gammaplex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,470.88 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Wolff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.